Overview
flowchart TD
clinical_trials["Clinical Trials"]
style clinical_trials fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_0["Current Pipeline Statistics"]
clinical_trials -->|"includes"| clinical_trials_0
style clinical_trials_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_1["Trials by Disease"]
clinical_trials -->|"includes"| clinical_trials_1
style clinical_trials_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_2["Trials by Status"]
clinical_trials -->|"includes"| clinical_trials_2
style clinical_trials_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_3["Trials by Phase"]
clinical_trials -->|"includes"| clinical_trials_3
style clinical_trials_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_4["Understanding Clinical Trial Phases"]
clinical_trials -->|"includes"| clinical_trials_4
style clinical_trials_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_5["Disease-Specific Trial Overview"]
clinical_trials -->|"includes"| clinical_trials_5
style clinical_trials_5 fill:#81c784,stroke:#333,color:#000
This index provides a comprehensive guide to clinical trials in neurodegenerative disease research, covering Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, frontotemporal dementia, and other related conditions. It serves as a central hub for understanding the drug development pipeline, trial methodologies, and outcomes across all phases of clinical research.
...Overview
Mermaid diagram (expand to render)
This index provides a comprehensive guide to clinical trials in neurodegenerative disease research, covering Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, frontotemporal dementia, and other related conditions. It serves as a central hub for understanding the drug development pipeline, trial methodologies, and outcomes across all phases of clinical research.
Clinical trials are essential for developing new treatments and understanding disease progression. Neurodegenerative diseases represent a significant global health burden, with over 50 million people affected by dementia worldwide and approximately 10 million living with Parkinson's disease. The translation of basic science discoveries into clinical applications depends critically on well-designed and executed clinical trials.
Current Pipeline Statistics
Trials by Disease
| Disease | Trials |
|---------|--------|
| ALZHEIMER | 4910 |
| PARKINSON | 4613 |
| ALS | 1569 |
| FTD | 380 |
| HUNTINGTON | 285 |
| MSA | 194 |
| DLB | 166 |
| VD | 154 |
| PSP | 154 |
| CBD | 60 |
Trials by Status
| Status | Trials |
|--------|--------|
| Recruiting | 1787 |
| Active Not Recruiting | 506 |
| Not Yet Recruiting | 594 |
| Completed | 6048 |
| Terminated | 737 |
| Withdrawn | 271 |
Trials by Phase
| Phase | Trials |
|-------|--------|
| PHASE1 | 1056 |
| PHASE1/PHASE2 | 381 |
| PHASE2 | 1544 |
| PHASE2/PHASE3 | 189 |
| PHASE3 | 816 |
| PHASE4 | 395 |
| EARLY_PHASE1 | 163 |
| NA | 4665 |
| Not Applicable | 2607 |
Total: 11816 trials | Active: 2887 trials
Last updated: 2026-03-18T05:22:53.984245+00:00
Understanding Clinical Trial Phases
Clinical trials proceed through distinct phases. Phase 1 trials focus on safety and dosage in a small group of 20-100 healthy volunteers or patients. Phase 2 trials evaluate efficacy and further assess safety in 100-300 patients. Phase 3 trials confirm efficacy and monitor adverse reactions in larger populations of 300-3,000 patients. Phase 4 trials occur after regulatory approval to monitor long-term effects.
Disease-Specific Trial Overview
Alzheimer's Disease Clinical Trials
Alzheimer's disease is the most common cause of dementia, affecting an estimated 6.5 million Americans. The AD drug development pipeline includes over 140 agents in various stages of clinical testing. Key trial endpoints include cognitive measures (ADAS-Cog, MoCA, CDR, MMSE), functional measures (ADCS-ADL, BADLS), and biomarkers (Amyloid PET, tau PET, CSF Aβ40/42, p-tau, neurofilament light).
Parkinson's Disease Clinical Trials
Parkinson's disease affects approximately 1 million Americans, with 60,000 new diagnoses annually. Trials focus on dopaminergic therapies, disease modification, and motor complication management. Key trial endpoints include motor assessments (MDS-UPDRS, Hoehn and Yahr scale), non-motor assessments (NMSS, PDQ-39), and motor complications scales.
ALS Clinical Trials
Amyotrophic lateral sclerosis affects approximately 30,000 Americans, with a median survival of 2-5 years. The FDA has approved only four treatments: riluzole, edaravone, sodium phenylbutyrate/taurursodiol, and tofersen. Key trial endpoints include functional measures (ALSFRS-R, ALS FVC), survival, and biomarkers (Neurofilament light chain).
How to Use This Index
Start with the alphabetical listing below to identify the page you need. Then use each page's See Also links to branch into related entities, mechanisms, or disease areas. Key resources for finding active trials include ClinicalTrials.gov, WHO ICTRP, and EU Clinical Trials Register.
Clinical Trials Pages (305 total)
Alzheimer's Disease Trials (71 trials)
- [A4 Study - Anti-Amyloid Treatment](/clinical-trials/a4-study)
- [ACP-204 - Alzheimer's Psychosis](/clinical-trials/acp-204-alzheimers-psychosis)
- [AL002 - TREM2 Agonist Alzheimer's](/clinical-trials/al002-trem2-agonist-alzheimers)
- [AMDX-2011P Phase 2 Alzheimer's](/clinical-trials/amdx-2011p-alzheimers-phase-2)
- [AMDX-2011P Retinal Amyloid Tracer AD](/clinical-trials/amdx-2011p-retinal-amyloid-tracer-ad)
- [BAN2401-201 - Lecanemab](/clinical-trials/ban2401-201)
- [Benfotiamine AD (NCT06223360)](/clinical-trials/benfotiamine-nct06223360-ad)
- [Bepranemab Tau Antibody Alzheimer's](/clinical-trials/bepranemab-tau-antibody-alzheimers)
- [BIIB080 MAPT Rx ASO Alzheimer's](/clinical-trials/biib080-maptrx-aso-alzheimers)
- [Blarcamesine Axon](/clinical-trials/blarcamesine-axon)
- [Caffeine AD (NCT04570085](/clinical-trials/caffeine-ad-nct04570085)
- [Choline 2 Donepezil (NCT04661280](/clinical-trials/choline-2-donepezil-nct04661280)
- [Crenezumab CREAD](/clinical-trials/crenezumab-cread)
- [DIAN-TU-001](/clinical-trials/dian-tu-001)
- [Donanemab TrailBlazer ALZ2](/clinical-trials/donanemab-trailblazer-alz2)
- [Donanemab TrailBlazer Open Label](/clinical-trials/donanemab-trailblazer-open-label)
- [E2814 4R-Tauopathy Phase 2](/clinical-trials/e2814-4r-tauopathy-phase-2-nct05615614)
- [E2814 Etanlanetug Tau Antibody](/clinical-trials/e2814-etanlanetug-tau-antibody)
- [EI-1071 Alzheimer's (NCT06745583](/clinical-trials/ei-1071-alzheimers-nct06745583)
- [Flornaptitril PET Alzheimer's](/clinical-trials/flornaptitril-pet-alzheimers)
- [Flornaptitril PET Phase 3](/clinical-trials/flornaptitril-pet-phase-3-nct06254469)
- [Gantenerumab GRADUATE](/clinical-trials/gantenerumab-graduate)
- [GV971 Sodium Oligomannurarate Phase 3](/clinical-trials/gv971-sodium-oligomannurarate-phase-3-nct05908695)
- [IGC-AD1 (NCT05543681](/clinical-trials/igc-ad1-nct05543681)
- [IL2 Immunotherapy AD (NCT06384378](/clinical-trials/il2-immunotherapy-ad-nct06384378)
- [KARXT AD Psychosis (NCT05511363](/clinical-trials/karxt-nct05511363-ad-psychosis)
- [KARXT AD Agitation (NCT06585787](/clinical-trials/karxt-nct06585787-ad-agitation)
- [KARXT (NCT07011745](/clinical-trials/karxt-nct07011745)
- [KDS2010 Phase 2 AD (NCT07027072](/clinical-trials/kds2010-phase2-ad-nct07027072)
- [Lecanemab Clarity AD](/clinical-trials/lecanemab-clarity-ad)
- [Lecanemab Clarity Open Label](/clinical-trials/lecanemab-clarity-open-label)
- [Lemborexant AD (NCT06274528](/clinical-trials/lemborexant-ad-nct06274528)
- [Levetiracetam Alzheimer's (NCT03875638](/clinical-trials/levetiracetam-alzheimers-nct03875638)
- [Levetiracetam Down Syndrome AD (NCT07234695](/clinical-trials/levetiracetam-down-syndrome-ad-nct07234695)
- [LHP588 P. gingivalis Alzheimer's](/clinical-trials/lhp588-p-gingivalis-alzheimers)
- [LHP588 Phase 2 P. gingivalis](/clinical-trials/lhp588-phase2-p-gingivalis-nct06847321)
- [LHP588 P. gingivalis (NCT06847321](/clinical-trials/lhp588-p-gingivalis-nct06847321)
- [Latrepirdine DMB-1 Phase 3](/clinical-trials/latrepirdine-dmb-1-phase-3)
- [ML-007C MA AD Psychosis (NCT06887192](/clinical-trials/ml-007c-ma-nct06887192-ad-psychosis)
- [MRI and Amyloid in Cognitive Decline](/clinical-trials/mri-amyloid-cognitive-decline-nct04363684)
- [Nabilone AD Agitation (NCT04516057](/clinical-trials/nabilone-ad-agitation-nct04516057)
- [NCT05399888 Biogen Alzheimer's Phase 2](/clinical-trials/nct05399888-biogen-alzheimers-phase2)
- [NCT07094516 Novartis Alzheimer's Phase 2](/clinical-trials/nct07094516-novartis-alzheimers-phase2)
- [NCT07284472 Exvivo Alzheimer's Phase 2-3](/clinical-trials/nct07284472-exciva-alzheimers-phase2-3)
- [NRTIs Alzheimer's (NCT04500847](/clinical-trials/nrtis-alzheimers-nct04500847)
- [ONO-2020 AD (NCT06881836](/clinical-trials/ono-2020-ad-nct06881836)
- [Pi-2620 Tau PET Phase 3](/clinical-trials/pi-2620-tau-pet-phase-3-nct05641688)
- [PLX5622 CSF1R AD (NCT05164068](/clinical-trials/plx5622-csf1r-ad-nct05164068)
- [Psilocybin MCI AD (NCT04123314](/clinical-trials/psilocybin-mci-ad-nct04123314)
- [Remternetug Anti-Amyloid Alzheimer's](/clinical-trials/remternetug-anti-amyloid-alzheimers)
- [Rotigotine Rivastigmine Combo](/clinical-trials/rotigotine-rivastigmine-combo-alzheimers)
- [Semaglutide EVOKE Plus AD (NCT04777409](/clinical-trials/semaglutide-evoke-plus-ad-nct04777409)
- [Seminarinemab TANGO](/clinical-trials/semorinemab-tango)
- [Simufilam Alzheimer's](/clinical-trials/simufilam-alzheimers)
- [SIPONIMOD AD (NCT06639282](/clinical-trials/siponimod-ad-nct06639282)
- [SNK01 NKGen Biotech Alzheimer's](/clinical-trials/snk01-nkgen-biotech-alzheimers)
- [Solanezumab A4](/clinical-trials/solanezumab-a4)
- [Suvorexant STOP AD (NCT04629547](/clinical-trials/suvorexant-stop-ad-nct04629547)
- [TYPHO1 Shanghai Auzone Phase 2 AD](/clinical-trials/ttyp01-shanghai-auzone-phase2-ad)
- [UB-311 Alzheimer's Vaccine](/clinical-trials/ub-311-alzheimers-vaccine)
- [Xanamem Phase 2 AD (NCT06125951](/clinical-trials/xanamem-phase2-ad-nct06125951)
- [Xpro1595 TNF Alpha Inhibitor Alzheimer's](/clinical-trials/xpro1595-tnf-alpha-inhibitor-alzheimers)
- [XTR006 Tau PET AD](/clinical-trials/xtr006-tau-pet-ad)
- [18F-PM-PBB3 PET Tauopathy](/clinical-trials/18f-pmbb3-pet-tauopathy-nct03625128)
- [AROs-MAPT SC (NCT07221344](/clinical-trials/aro-mapt-sc-tau-aso-nct07221344)
Parkinson's Disease Trials (68 trials)
- [AB-1005 GDNF Gene Therapy Regenerate PD](/clinical-trials/ab-1005-gdnf-gene-therapy-regenerate-pd)
- [AB-1005 GDNF Long-term Follow-up](/clinical-trials/ab-1005-gdnf-long-term-follow-up-nct07081841)
- [AB-1005 Regenerate PD GDNF Gene Therapy](/clinical-trials/ab-1005-regenerate-pd-gdnf-gene-therapy)
- [ABBV-951 Foslevodopa Foscarbidopa PD](/clinical-trials/abbv951-foslevodopa-foscarbidopa-pd)
- [ACI-35 Alpha-Synuclein Vaccine](/clinical-trials/aci-35-alpha-synuclein-vaccine)
- [AI-Enhanced Levodopa Challenge Test](/clinical-trials/ai-enhanced-levodopa-challenge-test-nct06949865)
- [AI Facial Speech Patterns PD (NCT07392411](/clinical-trials/ai-facial-speech-patterns-pd-nct07392411)
- [Ambroxol Aspro PD](/clinical-trials/ambroxol-aspro-pd)
- [APOCYNIN PD](/clinical-trials/apocynin-pd)
- [ARC-IM Adaptive Neurostimulation](/clinical-trials/arc-im-adaptive-neurostimulation-parkinsons)
- [Azilect ADAGIO](/clinical-trials/azilect-adagio)
- [Bacillus Subtilis PD](/clinical-trials/bacillus-subtilis-pd)
- [BIA 28-6156 GBA Parkinson's](/clinical-trials/bia-28-6156-gba-parkinsons)
- [BLAAC PD (NCT06719583](/clinical-trials/blaac-pd-nct06719583)
- [Brain Activity Walking Atypical Parkinsonism](/clinical-trials/brain-activity-walking-atypical-parkinsonism-nct06906276)
- [Circuit-Based DBS Parkinson's](/clinical-trials/circuit-based-dbs-parkinson)
- [Circuit-Based DBS (NCT05658302](/clinical-trials/circuit-based-dbs-nct05658302)
- [CNversyt Megan Rodney](/clinical-trials/cnversyt-megan-rodney)
- [Combination Therapy Biomarker Validation](/clinical-trials/combination-therapy-biomarker-validation)
- [CoQ10 QE3](/clinical-trials/coq10-qe3)
- [Cue1 Device PD (NCT06174948](/clinical-trials/cue1-device-pd-nct06174948)
- [CVN424 Phase 3 ARISE PD](/clinical-trials/cvn424-phase-3-arise-pd)
- [D-Serine Spark Parkinson's](/clinical-trials/d-spark-d-serine-parkinsons)
- [D-Serine Spark (NCT07312110](/clinical-trials/d-spark-d-serine-parkinsons-nct07312110)
- [DBS NBM (NCT07218081](/clinical-trials/dbs-nbm-nct07218081)
- [Digital Diagnostic Parkinson's (NCT06663826](/clinical-trials/digital-diagnostic-parkinsons-nct06663826)
- [Exenatide Parkinson's](/clinical-trials/exenatide-parkinsons)
- [Gait Analysis Upper Limb Evaluation](/clinical-trials/gait-analysis-upper-limb-evaluation-nct07136844)
- [Gantenerumab GRADUATE](/clinical-trials/gantenerumab-graduate)
- [Health Services Quality Life Atypical Parkinsonism](/clinical-trials/health-services-quality-life-atypical-parkinsonism-nct06645626)
- [Inclisiran Lewy Bodies](/clinical-trials/inclisiran-lewy-bodies)
- [Inosine SURVEY-PD3](/clinical-trials/inosine-sure-pd3)
- [Integrated Management Atypical Parkinsonism](/clinical-trials/integrated-management-atypical-parkinsonism-nct05792332)
- [Intranasal Insulin Glutathione PD](/clinical-trials/intranasal-insulin-glutathione-pd)
- [IRLT57 PD Apathy](/clinical-trials/irl757-pd-apathy)
- [KP405 PD (NCT06189170](/clinical-trials/kp405-pd-nct06189170)
- [Lenrispodun PD (NCT05766813](/clinical-trials/lenrispodun-pd-nct05766813)
- [MR-Guided Focused Ultrasound GCASE PD](/clinical-trials/mr-guided-focused-ultrasound-gcase-pd)
- [NAdapt Study NAD Replenishment Parkinsonism](/clinical-trials/nadapt-study-nad-replenishment-parkinsonism-nct06162013)
- [NCT05266417 Nose PD](/clinical-trials/nct05266417-nose-pd)
- [NCT06365190 RTMS PD](/clinical-trials/nct06365190-rtms-pd)
- [NCT06487975 Bacillus Subtilis PD](/clinical-trials/nct06487975-bacillus-subtilis-pd)
- [Nilotinib Parkinson's (NCT03744468](/clinical-trials/nilotinib-parkinsons-nct03744468)
- [NouvNeu001 PD](/clinical-trials/nouvneu001-pd)
- [Olfactory Mucosa Early Neurodegeneration](/clinical-trials/olfactory-mucosa-early-neurodegeneration-nct06846658)
- [Pain Autonomic Symptoms Parkinsonism](/clinical-trials/pain-autonomic-symptoms-parkinsonism-nct05748028)
- [PD-1001 Gene Therapy](/clinical-trials/parkinsons-disease)
- [PDE4 Inhibitor PD](/clinical-trials/pde4-inhibitor-pd)
- [Personalized Parkinson Project (NCT03364894](/clinical-trials/personalized-parkinson-project-nct03364894)
- [Pexidartinib PLX3397 CSF1R Parkinson's](/clinical-trials/pexidartinib-plx3397-csf1r-parkinsons-nct04888966)
- [Pi3K Akt Activator PD](/clinical-trials/pi3k-akt-activator-pd)
- [Pramipexole Early PD](/clinical-trials/pramipexole-early-pd)
- [Psilocybin Parkinson's Depression (NCT06455293](/clinical-trials/psilocybin-parkinsons-depression-nct06455293)
- [Retigabine PD](/clinical-trials/retigabine-pd)
- [TDCS Dysphagia Parkinson (NCT07153692](/clinical-trials/tdcs-dysphagia-parkinson-nct07153692)
- [TDCS Intensity (NCT05509387](/clinical-trials/tdcs-intensity-nct05509387)
- [TDCS PD Gait (NCT06324448](/clinical-trials/tdcs-pd-gait-nct06324448)
- [Urolithin A Parkinson's (NCT06033890](/clinical-trials/urolithin-a-parkinsons-nct06033890)
- [Valacyclovir HSV1 PD](/clinical-trials/valacyclovir-hsv1-pd)
- [Vibrotactile Coordinated Reset PD](/clinical-trials/vibrotactile-coordinated-reset-pd)
- [VNS PD (NCT07226284](/clinical-trials/vns-pd-nct07226284)
- [千金藤素 PD](/clinical-trials/千金藤素-pd)
Progressive Supranuclear Palsy Trials (42 trials)
- [AMX0035 PSP](/clinical-trials/amx0035-psp)
- [ART Therapy PSP (NCT06588673](/clinical-trials/art-therapy-psp-nct06588673)
- [Autonomic Function PSP (NCT06490926](/clinical-trials/autonomic-function-psp-nct06490926)
- [Bepranemab PSP Phase 2 (NCT05318985](/clinical-trials/bepranemab-psp-phase-2-nct05318985)
- [BIIB080 MAPT Rx PSP](/clinical-trials/biib080-maptrx-psp)
- [CoQ10 PSP (NCT00532571](/clinical-trials/coq10-psp-nct00532571)
- [CoQ10 PSP NICE (NCT04564555](/clinical-trials/coq10-psp-nice-nct04564555)
- [CurePSP Genetics Program](/clinical-trials/curepsp-genetics-program)
- [Davunetide AL108 PSP](/clinical-trials/davunetide-al108-psp)
- [FEEMSA Laryngopharyngeal PSP (NCT04706234](/clinical-trials/feemsa-laryngopharyngeal-psp-nct04706234)
- [First Human 4R-Tau Ligand PSP](/clinical-trials/first-human-4r-tau-ligand-psp)
- [First Human 4R-Tau Ligand PSP (NCT07348276](/clinical-trials/first-human-4r-tau-ligand-psp-nct07348276)
- [FNP223 PSP PROSPER](/clinical-trials/fnp223-psp-prosper)
- [Fundusography PSP (NCT07000851](/clinical-trials/fundus-ography-psp-nct07000851)
- [Gait Pattern Analysis PSP (NCT02994719](/clinical-trials/gait-pattern-analysis-psp-nct02994719)
- [Gait Upper Limb Evaluation PSP (NCT07136844](/clinical-trials/gait-upper-limb-evaluation-psp-nct07136844)
- [Gosuranemab BIIIB092 PSP](/clinical-trials/gosuranemab-biiib092-psp)
- [GV1001 PSP](/clinical-trials/gv1001-psp)
- [Lithium PSP](/clinical-trials/lithium-psp)
- [Lithium PSP Phase 2 (NCT05297202](/clinical-trials/lithium-psp-phase-2-nct05297202)
- [Motive PSP Initiative](/clinical-trials/motive-psp-initiative)
- [NAdapt PSP](/clinical-trials/nadapt-psp)
- [Neflamapimod PSP](/clinical-trials/neflamapimod-psp)
- [Neurologic Stem Cell Treatment PSP (NCT02795052](/clinical-trials/neurologic-stem-cell-treatment-psp-nct02795052)
- [NIH CTSA PSP Biospecimen (NCT05067192](/clinical-trials/nih-ctsa-psp-biospecimen-nct05067192)
- [NIO752 PSP](/clinical-trials/nio752-psp)
- [NIO752 PSP Tau ASO (NCT04539041](/clinical-trials/nio752-psp-tau-aso-nct04539041)
- [Pi-2620 PSP Tau PET](/clinical-trials/pi2620-psp-tau-pet)
- [PSP Clinical Trial Platform](/clinical-trials/psp-clinical-trial-platform)
- [PSP Clinical Trial Platform (NCT07173803](/clinical-trials/psp-clinical-trial-platform-nct07173803)
- [Quality of Life PSP Caregiver (NCT03638505](/clinical-trials/quality-of-life-psp-caregiver-nct03638505)
- [Remote Monitoring PSP (NCT04753320](/clinical-trials/remote-monitoring-psp-nct04753320)
- [Rock Inhibitor Fasudil PSP/CBS (NCT04734379](/clinical-trials/rock-inhibitor-fasudil-psp-cbs-nct04734379)
- [Swedish BioFinder 2 PSP (NCT03174938](/clinical-trials/swedish-biofinder-2-psp-nct03174938)
- [SYDE Digital Endpoints PSP](/clinical-trials/syde-digital-endpoints-psp)
- [TDCS Motor Function PSP (NCT07291687](/clinical-trials/tdcs-motor-function-psp-nct07291687)
- [Telephone Cognitive Assessment PSP (NCT06932809](/clinical-trials/telephone-cognitive-assessment-psp-nct06932809)
- [Tetrabenazine PSP](/clinical-trials/tetrabenazine-psp)
- [Tilavonemab PSP](/clinical-trials/tilavonemab-psp)
- [Tolfenamic Acid PSP (NCT04253132](/clinical-trials/tolfenamic-acid-psp-nct04253132)
- [TPN-101 PSP](/clinical-trials/tpn101-psp)
- [TPN-101 PSP (NCT04993768](/clinical-trials/tpn101-psp-nct04993768)
- [Transcranial Magnetic Stimulation PSP (NCT04468932](/clinical-trials/transcranial-magnetic-stimulation-psp-nct04468932)
- [Typhane PSP](/clinical-trials/typhane-psp)
- [UCB0107 PSP](/clinical-trials/ucb0107-psp)
- [Valproic Acid PSP (NCT00385710](/clinical-trials/valproic-acid-psp-nct00385710)
Amyotrophic Lateral Sclerosis Trials (24 trials)
- [Amiloride ALS](/clinical-trials/amiloride-als)
- [ATL1103 Antisense ALS](/clinical-trials/atl1103-antisense-als)
- [Ceftriaxone ALS](/clinical-trials/ceftriaxone-als)
- [Creatine ALS](/clinical-trials/creatine-als)
- [D-Cycloserine ALS](/clinical-trials/d-cycloserine-als)
- [Edaravone ALS](/clinical-trials/edaravone-als)
- [Gabapentin ALS](/clinical-trials/gabapentin-als)
- [Idebenone ALS](/clinical-trials/idebenone-als)
- [Immunoglobulin IVIG ALS](/clinical-trials/immunoglobulin-ivig-als)
- [Lithium Carbonate ALS](/clinical-trials/lithium-carbonate-als)
- [Lithium Continuation ALS](/clinical-trials/lithium-continuation-als)
- [Masitinib ALS](/clinical-trials/masitinib-als)
- [Minocycline ALS](/clinical-trials/minocycline-als)
- [Naltrexone ALS](/clinical-trials/naltrexone-als)
- [Nimodipine ALS](/clinical-trials/nimodipine-als)
- [Rapamycin ALS](/clinical-trials/rapamycin-als)
- [Riluzole ALS](/clinical-trials/riluzole-als)
- [Sodium Phenylbutyrate ALS](/clinical-trials/sodium-phenylbutyrate-als)
- [Tauraso Nimodipine ALS](/clinical-trials/tauraso-nimodipine-als)
- [Tofersen VALOR](/clinical-trials/tofersen-valor)
- [Vitamins ALS](/clinical-trials/vitamins-als)
- [AMX0035 Centaur](/clinical-trials/amx0035-centaur)
- [CNV1010102 ALS](/clinical-trials/cnversyt-megan-rodney)
Frontotemporal Dementia Trials (6 trials)
- [Cortisone FTD](/clinical-trials/cortisone-ftd)
- [Diagnosing FTD (NCT02964637](/clinical-trials/diagnosing-ftld-nct02964637)
- [Genetic Frontotemporal Dementia (NCT05653778](/clinical-trials/genetic-frontotemporal-dementia-nct05653778)
- [CPG1018 TLR9 (NCT05606341](/clinical-trials/cpg1018-tlr9-nct05606341)
- [Fronto-temporal Dementia Overview](/clinical-trials/progressive-supranuclear-palsy)
Multiple System Atrophy Trials (6 trials)
- [BLD-2660 MSA (NCT05224379](/clinical-trials/bld-2660-msa-nct05224379)
- [Cinumercept MSA (NCT04449485](/clinical-trials/cinumercept-msa-nct04449485)
- [Integrated Management Atypical Parkinsonism](/clinical-trials/integrated-management-atypical-parkinsonism-nct05792332)
- [Synaptic Loss MSA (NCT05121012](/clinical-trials/synaptic-loss-msa-nct05121012)
Huntington's Disease Trials (2 trials)
- [Huntington's Disease Overview](/clinical-trials/alzheimers-disease)
Other Neurodegenerative Trials (16 trials)
- [Bilingual Advantage AD](/clinical-trials/bilingual-advantage-ad)
- [Depression AD Citalopram](/clinical-trials/depression-ad-citalopram)
- [Daridorexant AD (NCT07213349](/clinical-trials/daridorexant-ad-nct07213349)
- [Daridorexant Post-Cardiotomy Delirium (NCT07217912](/clinical-trials/daridorexant-post-cardiotomy-delirium-nct07217912)
- [Methylphenidate ITBS Apathy AD](/clinical-trials/methylphenidate-itbs-apathy-ad)
- [Methylphenidate TDCS Alzheimer's](/clinical-trials/methylphenidate-tdcs-alzheimers)
- [Nabilone NAB-IT](/clinical-trials/nabilone-nab-it)
- [NCT05303701](/clinical-trials/nct05303701)
- [NCT06189963 SNK01 NKGen Alzheimer's](/clinical-trials/nct06189963-snk01-nkgen-alzheimers)
- [North American Prodromal Synucleinopathy Consortium (NCT05826457](/clinical-trials/north-american-prodromal-synucleinopathy-consortium-nct05826457)
- [Proteinopathies Skin Neurodegenerative Disorders (NCT06528964](/clinical-trials/proteinopathies-skin-neurodegenerative-disorders-nct06528964)
- [STAREES Statin Dementia Prevention](/clinical-trials/staree-statin-dementia-prevention)
- [Vcycle Virtual Cycling (NCT04804202](/clinical-trials/vcycle-virtual-cycling-nct04804202)
- [VCycle Virtual Cycling (NCT04804202](/clinical-trials/vcycle-virtual-cycling-nct04804202)
- [EMST SpiroGym PD (NCT06942533](/clinical-trials/emst-spirogym-pd-nct06942533)
- [Therapeutics](/therapeutics) — Drug therapies in trials
- [Diseases](/diseases) — Disease clinical studies
- [Biomarkers](/biomarkers) — Biomarker trials
- [Companies](/companies) — Trial sponsors
- [Institutions](/institutions) — Trial sites
See Also
- [NeuroWiki Home](/home)
- [All Pages](/all-pages)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
- [Entities Index](/entities)
External Links
- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [NIH NIA Alzheimer Research](https://www.nia.nih.gov/research/alzheimers)
- [Michael J. Fox Foundation](https://www.michaeljfox.org/)
References
Cummings JL, Tong G, Ballard C, "Treatment combinations for Alzheimer's disease." J Alzheimers Dis (2021)
Unknown, GBD 2019 Dementia Forecasting Collaborators. "Estimation of the global prevalence of dementia in 2019." Lancet Neurol. 2022;21(2):203-206 (2019)
Poewe W, Seppi K, Tanner CM, et al, "Parkinson disease." Nat Rev Dis Primers (2017)
Brown RH, Al-Chalabi A, "Amyotrophic lateral sclerosis." N Engl J Med (2017)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: TREM2
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: BCL2L1
- [Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PVALB
- [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
- [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
- [Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation](/hypothesis/h-fb56c8a0) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: SDC1
Related Analyses:
- [CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
- [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄